9-(3,4-Dichlorophenyl)-2,3,4,5,6,7,9,10-octahydroacridine-1,8-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 9-(3,4-Dichlorophenyl)-2,3,4,5,6,7,9,10-octahydroacridine-1,8-dione
• 化学式: C₁₉H₁₇Cl₂NO₂
• 分子量: 362.2
• InChiKey: QEXMYNHWSQXBPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
  申请人：Zhang Jun Jin

  公开号：US20050159410A1

  公开（公告）日：2005-07-21

  A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and/or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and/or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.

  一种用于预防后囊膜混浊的治疗方案被应用或引入到白内障手术之前、期间或之后的晶状体囊袋中。治疗方案也可以在手术前应用于人工晶体。该治疗方案包括离子传输机制干扰剂，该干扰剂单独或与其他治疗剂（如渗透应激剂和用于建立适当pH的剂）结合使用，有选择地诱导晶状体上皮细胞的脱离和/或死亡，从而预防后囊膜混浊。虽然离子传输机制干扰剂能够干扰广泛范围细胞的细胞机制和细胞离子分布，但选择了一定浓度的干扰剂，使治疗方案有选择性地干扰晶状体上皮细胞的细胞机制，同时基本不伤害其他眼部细胞。该治疗方案有选择性地诱导晶状体上皮细胞的细胞死亡和/或脱离，而其他眼部细胞和组织基本不受伤害，并且无需冗长的术前预处理。
• Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
  申请人：Herlands Louis

  公开号：US20070026079A1

  公开（公告）日：2007-02-01

  Provided are methods of increasing K ATP channel activity in the hypothalamus of a mammal, methods of reducing glucose production in a mammal, methods of reducing peripheral glucose levels in a mammal, methods of reducing triglyceride levels in a mammal, methods of reducing very low density lipoprotein (VLDL) levels in a mammal, methods of methods of reducing gluconeogenesis in the liver of a mammal, methods of treating metabolic disorders such as diabetes, hyperglycemia, insulin resistance, glucose intolerance, metabolic syndrome and/or obesity, and methods of increasing glucose production and peripheral glucose levels in a mammal. Also provided are methods of treating heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, atherosclerosis, hypercholesterolemia, hypertension, polycystic ovary syndrome, gonadotropin deficiency and/or amenorrhea.
• Modulation of Hypothalamic Atp-Sensitive Potassium Channels
  申请人：Rossetti Luciano

  公开号：US20090012067A1

  公开（公告）日：2009-01-08

  Provided are methods of increasing K ATP activity in the hypothalamus of a mammal, methods of reducing glucose production and peripheral blood glucose levels in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, and methods of increasing glucose production and peripheral blood glucose levels in a mammal.
• TREATMENT SOLUTION AND METHOD FOR PREVENTING POSTERIOR CAPSULAR OPACIFICATION BY SELECTIVELY INDUCING DETACHMENT AND/OR DEATH OF LENS EPITHELIAL CELLS
  申请人：Zhang JinJun

  公开号：US20110118174A1

  公开（公告）日：2011-05-19

  A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and/or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and/or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.
• US7875270B2
  申请人：——

  公开号：US7875270B2

  公开（公告）日：2011-01-25